Metabolic Dysfunction-Associated Fatty Liver Disease and Fibrosis Status in Patients with Type 2 Diabetes Treated at Internal Medicine Clinics: Türkiye DAHUDER Awareness of Fatty Liver Disease (TR-DAFLD) Study.

Autor: Şahintürk Y; Department of Internal Medicine, University of Health Sciences Antalya Training and Research Hospital, Antalya, Türkiye., Köker G; Department of Internal Medicine, University of Health Sciences Antalya Training and Research Hospital, Antalya, Türkiye., Koca N; Department of Internal Medicine, Bursa City Hospital, Bursa, Türkiye., Sümbül HE; Department of Internal Medicine, Adana City Hospital, Adana, Türkiye., Demir İ; Department of Internal Medicine, University of Health Sciences Bozyaka Training and Research Hospital, İzmir, Türkiye., Keskin H; Department of Internal Medicine, Ankara University Faculty of Medicine, Ankara, Türkiye., Yaylacı S; Department of Internal Medicine, Sakarya University Faculty of Medicine, Sakarya, Türkiye., Solmaz İ; Department of Internal Medicine, University of Health Sciences Diyarbakır Gazi Yaşargil Training and Research Hospital, Diyarbakır, Türkiye., Açmaz B; Department of Internal Medicine, Kayseri City Hospital, Kayseri, Türkiye., Yıldız H; Department of Internal Medicine, Gaziantep University Faculty of Medicine, Gaziantep, Türkiye., Ocak Serin S; Department of Internal Medicine, University of Health Sciences Ümraniye Training and Research Hospital, İstanbul, Türkiye., Taşçı Ş; Department of Internal Medicine, Karadeniz Technical University Faculty of Medicine, Trabzon, Türkiye., Ayaz T; Department of Internal Medicine, Rize University Faculty of Medicine, Rize, Türkiye., Araç E; Department of Internal Medicine, Dicle University Faculty of Medicine, Diyarbakır, Türkiye., Sözel H; Department of Internal Medicine, Akdeniz University Faculty of Medicine, Antalya, Türkiye., Kırık A; Department of Internal Medicine, Balıkesir University Faculty of Medicine, Balıkesir, Türkiye., Önmez A; Department of Internal Medicine, Düzce University Faculty of Medicine, Düzce, Türkiye., Kır S; Department of Internal Medicine, Ondokuz Mayıs University Faculty of Medicine, Samsun, Türkiye., Şen H; Department of Internal Medicine, Balıkesir University Faculty of Medicine, Balıkesir, Türkiye., Oral A; Department of Internal Medicine, Biruni University Faculty of Medicine, İstanbul, Türkiye., Arıcı FN; Department of Internal Medicine, Adana City Hospital, Adana, Türkiye., Kanat M; Department of Internal Medicine, İstanbul Medeniyet University Faculty of Medicine, İstanbul, Türkiye., Çekin AH; Department of Gastroenterology, University of Health Sciences Antalya Training and Research Hospital, Antalya, Türkiye., Uyar S; Department of Internal Medicine, University of Health Sciences Antalya Training and Research Hospital, Antalya, Türkiye.
Jazyk: angličtina
Zdroj: The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology [Turk J Gastroenterol] 2024 Jun 06; Vol. 35 (8), pp. 643-650.
DOI: 10.5152/tjg.2024.24045
Abstrakt: This awareness study aimed to determine the ultrasound (US) examination rates in relation to US-confirmed metabolic dysfunction-associated fatty liver disease (MAFLD) diagnosis in internal medicine outpatients with type 2 diabetes (T2D) across Türkiye. A total of 6283 T2D patients were included in this multicenter retrospective cohort study conducted at 17 internal medicine clinics across Türkiye. The presence and indications for US performed within the last 3 years were recorded along with US-confirmed MAFLD rates, laboratory findings on the day of US, and referral rates. Fibrosis-4 (FIB-4) index was calculated to estimate the risk of advanced liver fibrosis (FIB-4 index ≥ 1.3). Overall, 1731 (27.6%) of 6283 patients had US examination, which revealed MAFLD diagnosis in 69.9% of cases. In addition, 24.4% of patients with US-confirmed MAFLD were at risk of advanced fibrosis (FIB-4 index ≥ 1.3), and the referral rate was 15.5%. In conclusion, our findings emphasize an insufficient MAFLD awareness among clinicians and the likelihood of most of T2D patients to be at risk of living with an unknown status regarding their MAFLD and advanced fibrosis risk.
Databáze: MEDLINE